Damora Therapeutics Inc.

GLTO | NASDAQ

Price Alert Chart Builder DCF Calculator

$21.58

-$0.75 (-3.36%)

At close: Jun 4, 2026, 12:02 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $34.47M

Enterprise Value $-497.09M

Beta 1.60

Average Volume N/A

Shares Outstanding (Diluted) 1.6M

Shares Change YoY 20.83%

Institutional Ownership N/A

Exchange N/A

ISIN N/A

Price Performance

Price Change 1M -14.2%

Price Change 3M -25.4%

Price Change 6M -16.1%

Price Change YTD -1.1%

Price Change 1Y 553.9%

Price Change 3Y -60.6%

Price Change 5Y -84.6%

1M CAGR (ann.) -13.2%

1Y CAGR (ann.) 647.6%

5Y CAGR (ann.) -28.6%

All-Time CAGR -39.3%

Valuation

PE Ratio -1.08

Forward PE N/A

PEG Ratio 0.00

Forward PEG -0.06

PS Ratio N/A

Forward PS 1.60

PB Ratio 0.07

P/FCF Ratio -1.39

P/Adj. FCF Ratio -1.34

P/OCF Ratio -7.93

EV/Sales N/A

EV/EBIT 2.08

EV/EBITDA 2.08

EV/FCF 19.98

Earnings Yield -92.9%

FCF Yield -72.2%

Adj. FCF Yield -74.6%

Financial Health

Net Cash $531.56M

Total Debt $1.34M

Cash & Short-Term Investments $532.9M

Total Assets $535.44M

Current Ratio 19.73

Quick Ratio 19.73

Debt / Equity Ratio 0.00

Debt / EBITDA -0.01

Debt / FCF -0.05

OCF / Debt -18.56

Interest Coverage 0.00

Altman Z-Score -0.84

Piotroski F-Score 3

Margins & Profitability

Gross Profit Margin 0.0%

Operating Profit Margin 0.0%

EBITDA Margin 0.0%

Net Profit Margin 0.0%

FCF Margin N/A

Adj. FCF Margin N/A

SBC / Revenue 0.0%

SBC Impact (per share) -3.3%

Returns

Return on Assets -48.4%

Return on Equity -82.6%

Return on Invested Capital -52.4%

Return on Capital Employed -52.4%

Return on Tangible Assets -48.4%

Historical Growth (CAGR)

Revenue CAGR 3Y N/A

Revenue CAGR 5Y N/A

Revenue CAGR 10Y N/A

EPS CAGR 3Y 20.1%

EPS CAGR 5Y 31.2%

EPS CAGR 10Y N/A

FCF CAGR 3Y 18.0%

FCF CAGR 5Y 21.6%

FCF CAGR 10Y N/A

Analyst Forecasts

Analyst Rating Buy

Analyst Count 5

EPS Growth Next 3Y 29.3%

Revenue Growth Next 3Y N/A

Earnings Date Aug 4, 2026

EPS Estimate (next Q) -$0.45

EPS Growth Est (next Q) -82.8%

Revenue Est (next Q) N/A

Revenue Growth Est (next Q) N/A

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $35.25

Price Target Upside 63.3%

Cash Flow

Operating Cash Flow $-24.89M

Free Cash Flow $-24.89M

Adj. Free Cash Flow $-25.7M

FCF Per Share -$2.72

OCF Per Share -$2.72

OCF/S Ratio 0.0%

Income Statement

Revenue $0

Gross Profit $-68K

Operating Income $-239.08M

EBITDA $-238.97M

Net Income $-235.09M

EPS (Diluted) -$20.04

Revenue / Employee N/A

Profit / Employee N/A

Employees N/A